Bristol-Myers Squibb continues to expand its portfolio and strengthen its position within the biotech industry with multiple key FDA approvals including Sotyktu for psoriatic arthritis and Breyanzi for relapsed or refractory marginal zone lymphoma. The company also explores innovative therapies with the creation of a new company dedicated to developing innovative immunology therapies and recent collaborations for antibody discovery and development. Despite several investment groups selling their shares, others like IFG Advisory LLC, Focus Partners Advisor Solutions LLC, and Crossmark Global Holdings Inc. have increased their stakes in Bristol-Myers Squibb. The company has been identified as a strong dividend stock and has recently declared a quarterly dividend of $0.63. Major market players like UBS and JP Morgan express their bullish outlook on BMY by increasing its price target and acknowledging its 'deep value.' In a controversial move, Bristol-Myers Squibb plans to divest its 60% stake in a China JV and discloses layoffs amid strategic realignment.
Bristol-Myers Squibb News Analytics from Wed, 14 May 2025 07:00:00 GMT to Sat, 07 Mar 2026 22:58:10 GMT -
Rating 6
- Innovation 7
- Information 9
- Rumor -2
